Oxford Cannabinoid De-List from the LSE To Pursue Private Funding To Accelerate Development #octp

StockBox

10.8K subscribers

ShareSubscribe

Oxford Cannabinoid de-list from the LSE with the aim to reset the company's valuation and facilitating drug development without the limitations of a low public market valuation. This strategic move is unanimously supported by the board, who view it as an opportunity to advance their drug development programs more efficiently. CEO Clarissa acknowledges the potential disappointment among shareholders, especially those who invested at higher prices. To mitigate these concerns, the company are looking at a matched bargain facility to allow shareholders to trade their shares even after de-listing. Clarissa expresses confidence in the company's future and encourages shareholders to see the de-listing as a strategic move to potentially increase their investments' value in the future. Clarissa reassures that the company remains operationally robust, with no immediate cash flow concerns and no debt. She outlines the progress in their drug development pipeline, including a successful Phase 1 trial and the initiation of additional trials in Australia. The goal is to eventually return to the public market, potentially on NASDAQ, once the company is in a stronger position. By Mark Fairbairn Recorded 8//5/2024